Male BRCA2 mutation carriers are recommended to undergo prostate cancer surveillance through measuring PSA, digital rectal exams, and prostate USG over 40 years of age, and this could also be considered for BRCA1 mutation carriers. This evidence concerns the gene BRCA2 and prostate carcinoma.